BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32011516)

  • 1. Case Report of acute myeloid leukemia with "WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19" developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy.
    Zhu H; Yang B; Liu J; Wu W; Ling Y
    Medicine (Baltimore); 2020 Jan; 99(3):e18888. PubMed ID: 32011516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
    Nakamura F; Arai H; Nannya Y; Ichikawa M; Furuichi S; Nagasawa F; Takahashi W; Handa T; Nakamura Y; Tanaka H; Nakamura Y; Sasaki K; Miyano S; Ogawa S; Mitani K
    Int J Hematol; 2021 Jun; 113(6):936-940. PubMed ID: 33400143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of AML without karyotype abnormalities including the Ph chromosome in a CML patient on second-generation TKI therapy].
    Sakai T; Konuma Y; Shimoyama S; Kohda K
    Rinsho Ketsueki; 2016; 57(11):2329-2333. PubMed ID: 27941281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
    Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
    Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].
    Yuan T; Wang XY; Lai YY; Qin YZ; Shi HX; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):547-553. PubMed ID: 32397016
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors.
    Ni H; Sun X; Xu Y; Lyle D; Petersen P; Zhao X; Drum H; You B; Liu D; Liu C; Jiang JG
    Cancer Genet; 2019 Oct; 238():44-49. PubMed ID: 31425925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
    Crisan AM; Coriu D; Arion C; Colita A; Jardan C
    J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse and cytogenetic evolution in myeloid neoplasms.
    Ertz-Archambault N; Kelemen K
    Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex karyotype with double Philadelphia chromosome and T315I mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient.
    Davulcu EA; Pekerbas M; Karaca E; Durmaz B; Özsan N; Akın H; Saydam G
    Cancer Genet; 2022 Aug; 266-267():74-80. PubMed ID: 35843036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia.
    Wasilewska EM; Panasiuk B; Gniot M; Sawicka A; Kozłowska K; Lewandowski K; Kłoczko J; Midro AT
    Cancer Genet; 2017 Oct; 216-217():1-9. PubMed ID: 29025581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
    Cheng J; Liao Y; Bin T; OUYang J; Chen S; Chen X; Zou W
    Curr Med Res Opin; 2020 Nov; 36(11):1807-1812. PubMed ID: 32936052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
    Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
    Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosis of clonal chromosomal abnormalities in Philadelphia negative metaphases cells in chronic myeloid leukemia with tyrosine kinase inhibitor therapy].
    Zhao HF; Zhang Y; Hu JY; Li Z; Zhou J; Yu FK; Zu YL; Zhou H; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):209-214. PubMed ID: 30929388
    [No Abstract]   [Full Text] [Related]  

  • 15. BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone.
    Behrens YL; Schienke A; Davenport C; Lentes J; Tauscher M; Steinemann D; Rasche M; Knirsch S; Joachim S; Reinhardt D; Schlegelberger B; Göhring G
    Cancer Genet; 2021 Jun; 254-255():70-74. PubMed ID: 33647814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the Relationship between Cytogenetic Changes and Course Evolution of Patients with CML during TKI Treatment].
    Wang K; Liu T; Dai J; Pang YX; Wang Q
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):136-140. PubMed ID: 32027266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
    Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
    Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Kovitz C; Kantarjian H; Garcia-Manero G; Abruzzo LV; Cortes J
    Blood; 2006 Oct; 108(8):2811-3. PubMed ID: 16809614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
    Egan DN; Beppu L; Radich JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.